Rosa Allyn Sy

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

Hiddo J.L. Heerspink, C. David Sjöström, Niels Jongs et al. · European Heart Journal · 2021 · 118 citations · Full text

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek et al. · Circulation · 2022 · 112 citations · Full text

A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

Hiddo J.L. Heerspink, David Z.I. Cherney, Douwe Postmus et al. · Kidney International · 2021 · 92 citations · Full text

Reduction in size of a thyrotropin- and gonadotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog).

Rosa Allyn Sy, Robert Bernstein, K.-Y. Chynn et al. · The Journal of Clinical Endocrinology & Metabolism · 1992 · 38 citations

Pituitary Gland, Growth Hormone, Endocrine Mechanism +14

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

Gregory G. Schwartz, Michael Szarek, Vera Bittner et al. · Diabetes Care · 2021 · 32 citations · Full text